BSE filing, NSE: VENMAX. Summary written from the filing by ALFA Finder's alert engine.
Venmax Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹13.06
- Market cap
- ₹11.47 Cr
- Revenue (annual)
- ₹8.02 Cr
- Net profit (annual)
- ₹0.25 Cr
- P/E (TTM)
- 40.9×Sector 46.1×
- Promoter holding
- 10.46%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Venmax Drugs & Pharmaceuticals Ltd
All →Venmax Drugs & Pharmaceuticals Acquisition
Venmax Drugs' shareholders met on 24 October 2026 under an NCLT order to approve an amalgamation with Hatri Pharma. Voting results await the scrutinizer's report.
Venmax Drugs & Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern under Regulation 31(1)(b) of the SEBI LODR Regulations for the quarter ended September 30, 2026.
Venmax Drugs & Pharmaceuticals Annual General Meeting
Venmax Drugs and Pharmaceuticals held its 37th Annual General Meeting on September 26, 2026. Shareholders considered the financial statements and various directorship appointments.
Venmax Drugs & Pharmaceuticals Acquisition
Venmax Drugs and Pharmaceuticals Limited announced an NCLT-convened meeting of equity shareholders on October 24, 2026, to consider the proposed merger with Hatri Pharma Private Limited.
Venmax Drugs & Pharmaceuticals Acquisition
NCLT Hyderabad directed Venmax to convene a shareholder meeting on 24 Oct 2026 for the amalgamation of Hatri Pharma into Venmax. The order also dispensed with meetings of Hatri Pharma's shareholders and creditors.
Venmax Drugs & Pharmaceuticals Annual Report
Venmax Drugs and Pharmaceuticals Limited has submitted its Annual Report for the Financial Year 2025-26, including the Notice for its 37th Annual General Meeting.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.